Opexa Therapeutics CEO to Appear on The RedChip Money Report on Fox Business News Business Wire THE WOODLANDS, Texas -- October 17, 2013 Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna^®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Opexa will be highlighted in an upcoming broadcast of "The RedChip Money Report: Small Stocks Big Money," a nationally televised financial program. The broadcast will include an interview with Opexa's President and Chief Executive Officer, Neil K. Warma, and is scheduled to air on Thursday, October 17th at 10:00 p.m. PDT on the Fox Business Network. The interview will include a corporate update and financial highlights, as well as provide an overview of Opexa's ongoing Phase IIb clinical trial for Secondary Progressive MS, the Abili-T trial, being conducted in the United States and Canada. The "RedChip Money Report" segment from Fox Business will be made available on the investor relations page of Opexa's website. "The RedChip Money Report: Small Stocks Big Money"™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances on both CNBC and Fox Business News and has been a consultant to hundreds of public companies. About Opexa Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna^®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. About Multiple Sclerosis (MS) MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The Secondary Progressive form of MS represents about a third of the MS patient population. About Tcelna Tcelna^® is a potential personalized therapy that is under development to be specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPath™, Opexa's proprietary method for the production of a patient-specific T-cell immunotherapy, which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response. Opexa is currently conducting a Phase IIb study of Tcelna. Named "Abili-T," the trial is a randomized, double-blind, placebo-controlled clinical study in patients who demonstrate evidence of disease progression with or without associated relapses. The trial is expected to enroll 180 patients at approximately 30 leading clinical sites in the U.S. and Canada with each patient receiving two annual courses of Tcelna treatment consisting of five subcutaneous injections per year. The trial’s primary efficacy outcome is the percentage of brain volume change (atrophy) at 24 months. Study investigators will also measure several important secondary outcomes commonly associated with MS, including disease progression as measured by the Expanded Disability Status Scale (EDSS), annualized relapse rate and changes in disability as measured by EDSS and the MS Functional Composite. For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com. Contact: Company Contact: Karthik Radhakrishnan Opexa Therapeutics, Inc. Chief Financial Officer 281-775-0600 or Investor Relations: The Trout Group Adam Cutler 646-378-2936 firstname.lastname@example.org
Opexa Therapeutics CEO to Appear on The RedChip Money Report on Fox Business News
Press spacebar to pause and continue. Press esc to stop.